which generated $1.2 billion in sales last year and according to GlobalData could reach $9 billion by 2029. According to a recent Daiichi Sankyo business update (PDF), Dato-DXd will contribute to ...
The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan ... NeoADAURA in the neoadjuvant setting and ADAURA 2 in the adjuvant setting – that, if positive ...
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...